Literature DB >> 35633315

Racial disparities in epithelial ovarian cancer survival: An examination of contributing factors in the Ovarian Cancer in Women of African Ancestry consortium.

Holly R Harris1,2, Kristin A Guertin3, Tareq F Camacho4, Courtney E Johnson5, Anna H Wu6, Patricia G Moorman7, Evan Myers8, Traci N Bethea9, Elisa V Bandera10, Charlotte E Joslin11, Heather M Ochs-Balcom12, Lauren C Peres13, Will T Rosenow4, Veronica W Setiawan6, Alicia Beeghly-Fadiel14, Lauren F Dempsey5, Lynn Rosenberg15, Joellen M Schildkraut5.   

Abstract

Black women diagnosed with epithelial ovarian cancer have poorer survival compared to white women. Factors that contribute to this disparity, aside from socioeconomic status and guideline-adherent treatment, have not yet been clearly identified. We examined data from the Ovarian Cancer in Women of African Ancestry (OCWAA) consortium which harmonized data on 1074 Black women and 3263 white women with ovarian cancer from seven US studies. We selected potential mediators and confounders by examining associations between each variable with race and survival. We then conducted a sequential mediation analysis using an imputation method to estimate total, direct, and indirect effects of race on ovarian cancer survival. Black women had worse survival than white women (HR = 1.30; 95% CI 1.16-1.47) during study follow-up; 67.9% of Black women and 69.8% of white women died. In our final model, mediators of this disparity include college education, nulliparity, smoking status, body mass index, diabetes, diabetes/race interaction, postmenopausal hormone (PMH) therapy duration, PMH duration/race interaction, PMH duration/age interaction, histotype, and stage. These mediators explained 48.8% (SE = 12.1%) of the overall disparity; histotype/stage and PMH duration accounted for the largest fraction. In summary, nearly half of the disparity in ovarian cancer survival between Black and white women in the OCWAA consortium is explained by education, lifestyle factors, diabetes, PMH use, and tumor characteristics. Our findings suggest that several potentially modifiable factors play a role. Further research to uncover additional mediators, incorporate data on social determinants of health, and identify potential avenues of intervention to reduce this disparity is urgently needed.
© 2022 UICC.

Entities:  

Keywords:  disparities; ovarian cancer; survival

Mesh:

Year:  2022        PMID: 35633315      PMCID: PMC9420829          DOI: 10.1002/ijc.34141

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.316


  50 in total

1.  Bias formulas for sensitivity analysis for direct and indirect effects.

Authors:  Tyler J VanderWeele
Journal:  Epidemiology       Date:  2010-07       Impact factor: 4.822

2.  Recent Trends in Ovarian Cancer Incidence and Relative Survival in the United States by Race/Ethnicity and Histologic Subtypes.

Authors:  Hyo K Park; Julie J Ruterbusch; Michele L Cote
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2017-07-27       Impact factor: 4.254

3.  Disparities in ovarian cancer survival in the United States (2001-2009): Findings from the CONCORD-2 study.

Authors:  Sherri L Stewart; Rhea Harewood; Melissa Matz; Sun Hee Rim; Susan A Sabatino; Kevin C Ward; Hannah K Weir
Journal:  Cancer       Date:  2017-12-15       Impact factor: 6.860

4.  Use of hormone replacement therapy before and after ovarian cancer diagnosis and ovarian cancer survival.

Authors:  Chantal Mascarenhas; Mats Lambe; Rino Bellocco; Kjell Bergfeldt; Tomas Riman; Ingemar Persson; Elisabete Weiderpass
Journal:  Int J Cancer       Date:  2006-12-15       Impact factor: 7.396

5.  A multiethnic cohort in Hawaii and Los Angeles: baseline characteristics.

Authors:  L N Kolonel; B E Henderson; J H Hankin; A M Nomura; L R Wilkens; M C Pike; D O Stram; K R Monroe; M E Earle; F S Nagamine
Journal:  Am J Epidemiol       Date:  2000-02-15       Impact factor: 4.897

6.  Appropriate Systemic Therapy Dosing for Obese Adult Patients With Cancer: ASCO Guideline Update.

Authors:  Jennifer J Griggs; Kari Bohlke; Edward P Balaban; James J Dignam; Evan T Hall; R Donald Harvey; Diane P Hecht; Kelsey A Klute; Vicki A Morrison; T May Pini; Gary L Rosner; Carolyn D Runowicz; Michelle Shayne; Alex Sparreboom; Sophia Turner; Corrine Zarwan; Gary H Lyman
Journal:  J Clin Oncol       Date:  2021-05-03       Impact factor: 44.544

7.  Markers of inflammation and risk of ovarian cancer in Los Angeles County.

Authors:  Anna H Wu; Celeste L Pearce; Chiu-Chen Tseng; Claire Templeman; Malcolm C Pike
Journal:  Int J Cancer       Date:  2009-03-15       Impact factor: 7.396

8.  Understanding and addressing social determinants to advance cancer health equity in the United States: A blueprint for practice, research, and policy.

Authors:  Kassandra I Alcaraz; Tracy L Wiedt; Elvan C Daniels; K Robin Yabroff; Carmen E Guerra; Richard C Wender
Journal:  CA Cancer J Clin       Date:  2019-10-29       Impact factor: 508.702

9.  Invasive Epithelial Ovarian Cancer Survival by Histotype and Disease Stage.

Authors:  Lauren C Peres; Kara L Cushing-Haugen; Martin Köbel; Holly R Harris; Andrew Berchuck; Mary Anne Rossing; Joellen M Schildkraut; Jennifer A Doherty
Journal:  J Natl Cancer Inst       Date:  2019-01-01       Impact factor: 13.506

10.  Race, Socioeconomic Status, and Health-Care Access Disparities in Ovarian Cancer Treatment and Mortality: Systematic Review and Meta-Analysis.

Authors:  Shama Karanth; Mackenzie E Fowler; XiHua Mao; Lauren E Wilson; Bin Huang; Maria Pisu; Arnold Potosky; Tom Tucker; Tomi Akinyemiju
Journal:  JNCI Cancer Spectr       Date:  2019-10-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.